4D Molecular Therapeutics (FDMT) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$56.9 million.
- 4D Molecular Therapeutics' Income towards Parent Company fell 29.68% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 45.83%. This contributed to the annual value of -$160.8 million for FY2024, which is 59.74% down from last year.
- 4D Molecular Therapeutics' Income towards Parent Company amounted to -$56.9 million in Q3 2025, which was down 4.14% from -$54.6 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Income towards Parent Company registered a high of -$7.6 million during Q2 2021, and its lowest value of -$56.9 million during Q3 2025.
- For the 3-year period, 4D Molecular Therapeutics' Income towards Parent Company averaged around -$38.3 million, with its median value being -$34.9 million (2024).
- As far as peak fluctuations go, 4D Molecular Therapeutics' Income towards Parent Company soared by 60.71% in 2023, and later crashed by 334.17% in 2024.
- 4D Molecular Therapeutics' Income towards Parent Company (Quarterly) stood at -$25.1 million in 2021, then decreased by 9.20% to -$27.4 million in 2022, then decreased by 17.86% to -$32.3 million in 2023, then crashed by 53.85% to -$49.6 million in 2024, then dropped by 29.68% to -$56.9 million in 2025.
- Its Income towards Parent Company stands at -$56.9 million for Q3 2025, versus -$54.6 million for Q2 2025 and -$48.0 million for Q1 2025.